DOCSLIB.ORG

Tumor Lysis Syndrome Caused by Therapeutic Monoclonal Antibodies Approved by FDA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tumor Lysis Syndrome Caused by Therapeutic Monoclonal Antibodies Approved by FDA MOJ Immunology Tumor Lysis Syndrome Caused by Therapeutic Monoclonal Antibodies Approved by FDA Editorial Editorial Volume 5 Issue 5 - 2017 In 1975, Monoclonal antibody (mAb) technique was created Physiologyby Georges orKöhler, Medicine César in Milstein, 1984 for and the Nielsdiscovery. Kaj Jerne 8 years by usinglater, mouse x mouse hybridoma, they shared the Nobel Prize in Medical Director, Pharmacovigilance and Drug Safety, USA in 1992 FDA approved first therapeutic mAb Muromonab-CD3 *Corresponding author: Henry Hongrong Cai, Medical (trade name Orthoclone OKT3) to reduce acute rejection in Director, Pharmacovigilance and Drug Safety, inVentiv Health patients with organ transplants, since then, as of May 31, 2017, Clinical, 95 Cynthia Road Newton, MA 02459, USA, Tel: FDA has approved 70 therapeutic mAbs [1-3]. Among them 28 1-617-584-6628; Email: were approved for treatment of cancers (Table 1) [4-31]. These Received: June 05, 2017 | Published: June 06, 2017 therapeutic mAb targets at components expressed on cancer cell, possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC), antibody-dependent cell mediated cytotoxicity (ADCC), induced apoptosis, cancer cell growth inhibition, direct cytoxicities, and conjugates indirect effect resulting cancer cell antigensdeath (radiation chosen asor target,internalized they alsoderives). expressed Unfortunately, at normal so cells, far there is no tumor specific antigen (TSA) available for target, those which inevitably causes various adverse reactions, in this article, Table 1 tumor lysis syndrome (TLS) is briefly reviewed. : Monoclonal Antibodies for Cancer Therapy Approved By FDA. Drug Name Approval Date Company Active Integedients Target Indication Rituxan 11/26/1997 IDEC CD20 Herceptin 9/25/1998 Rituximab B-NHL Mylotarg 5/17/2000 GenetechWyeth Trastuzumab EGF BreastAML Ca Campath 2/7/2001 Gemtuzumab Ozogamicin CD33CD52 Zevalin 2/19/2002 SpectrumGenzyme Alemtuzumab CD20 B-CLL 2/12/2004 Imclone Ibritumomab Tiuxetan B-NHLMCC ErbituxAvastin 2/26/2004 Cetuximab VEGFR Colon Ca 9/27/2006 GenetechAmgen Bevacizumab VEGF Colorectal Ca Vectibix 10/26/2009 Panitumumab EGFRCD20 YervoyArzera Glaxo Ofatumumab CTLA-4 MelanomaB-CLL Adcetris 3/25/20118/19/2011 SeattleBMS Sci Ipilimumab HL 6/8/2012 Brentuximab Vedotin HER2CD30 Perjeta Genetech Pertuzumab HER2 Breast Ca Kadcyla 2/22/2013 Genetech Ado-Trastuzumab Emtansine CD20 Breast Ca Gazyva 11/1/20134/21/2014 GenetechEli Eilly Obinutuzumab B-CLL Cyramza 9/4/2014 MSD Ramucirumab VEGFR2PD-1 MelanomaGastric Ca Ketruda Amgen Pembrolizumab ALL Tositumomab; Iodine I 131 Bexxar 12/3/2014 CD19+CD3 Opdivo 12/22/2014 Tositumomab PD-1 Melanoma Unituxin UnitedBMS Terap Nivolumab 3/10/2015 Dinutuximab GD2 Neuroblastoma Submit Manuscript | http://medcraveonline.com MOJ Immunol 2017, 5(5): 00169 Copyright: Tumor Lysis Syndrome Caused by Therapeutic Monoclonal Antibodies Approved by FDA ©2017 Cai 2/3 11/16/2015 Janssen MM Darzalex 11/24/2015 Eli Eilly Daratumumab CD38 Lung cancer PortrazzaEmpliciti Necitumumab SLAMF7EGFR MM 11/30/20155/18/2016 BMS Elotuzumab PD-L1 Urothelial Ca Tecentiq 10/18/2016 Genetech Atezolizumab PD-L1 Metastatic NSCLC TecentriqLartruvo 10/19/2016 GenetechEli Eilly Atezolizumab soft tissue sarcoma EMD serono Olaratumab PDGFR-αPD-L1 Metastatic Merkel Cell Ca Bavencio 3/23/20175/1/2017 Avelumab PD-L1 Metastatic Urothelial Ca Imfinzi 5/9/2017 AstrazenecaEMD serono UK Durvalumab PD-L1 Metastatic Urothelial Ca Bavencio Avelumab CD: Cluster of Differentiation; EGF: Epidermal Growth Factor; VEGFR: Vascular Endothelial Growth Factor Receptor; VEGF: Vascular Endothelial Growth Factor; EGFR: Epidermal Growth Factor Receptor; CTLA-4: Cytotoxic T-Lymphocyte-Associated Protein 4; HER2: Human Epidermal Growth Factor Receptor 2; PD-1: Programmed Cell Death Protein 1; GD2: Glycolipid Disialoganglioside; SLAMF7: Signaling Lymphocytic Activation Molecule Family Member 7; PD-L1: Programmed Death-Ligand 1; B-NHL: B-Cell Non-Hodgkin’s Lymphoma; AML: Acute Myeloid Leukemia; B-CLL: B-Cell Chronic Lymphocytic Leukemia; MCC: Metastatic Colorectal Carcinoma; HL: Hodgkin’s Lymphoma; ALL: Acute Lymphocytic Leukemia; MM: Multiple Myeloma; PDGFR-α: Platelet-Derived Growth Factor Receptor Alpha; MCC: Merkel Cell Carcinoma lysis prophylaxis with anti-hyperuricemics (e.g., allopurinol TLS may be a consequence of liquid tumor treatment with Acutetherapeutic renal mAbsfailure, approved hyperkalemia, by FDA hypocalcemia, (Table 2), which hyperuricemia, is not seen withor rasburicase) hydroxyurea and or hydrationleukapheresis prior to toreduce the infusionthe peripheral of the orin thehyperphosphatemia labeling of therapeutic from tumor mAbs lysis, for solidsome tumor fatal, can(Table occur 3). therapeutic mAb. Physicians should also consider leukoreduction white blood count to < 30,000/µL prior to administration of the tumors,within 12-24 even targetinghours after same the antigen first infusionCD20, it mayof the not therapeutic cause TLS therapeutic mAb. During the initial days of treatment, monitor mAbs. Interestingly among those therapeutic mABs for liquid the laboratory parameters of patients considered at risk for TLS. circulating lymphocyte count (> 25 x 109 /L) or renal impairment includingFor treatment dialysis of TLS,as indicated. correct electrolyte abnormalities, monitor are(Table at greater2). It is risk believed for TLS patients and should with receive high tumor appropriate burden, tumor high renal function and fluid balance, and administer supportive care, Table 2: TherapeuticDrug Name MonoclonalApproval Antibodies Date for LiquidCompany Tumor Therapy ApprovedActive Integedients By FDA. Target Indication TLS Rituxan 11/26/1997 IDEC CD20 Yes 5/17/2000 Wyeth Rituximab* B-NHLAML Yes *MylotargCampath 2/7/2001 Gemtuzumab Ozogamicin CD33CD52 No 2/19/2002 SpectrumGenzyme Alemtuzumab CD20 B-CLL No Zevalin** 10/26/2009 Ibritumomab Tiuxetan CD20 B-NHL Yes Arzerra* 8/19/2011 SeattleGlaxo Sci Ofatumumab B-CLLHL Yes Adcetris* Brentuximab Vedotin CD30CD20 Yes Gazyva* 11/16/201511/1/2013 GenetechJanssen Obinutuzumab B-CLLMM No EmplicitiDarzalex Daratumumab SLAMF7CD38 MM No 11/30/2015 AmgenBMS Elotuzumab ALL N/A Tositumomab; Iodine I 131 Bexxar 12/3/2014 CD19+CD3 Table 3: Tositumomab DrugTherapeutic Name MonoclonalApproval AntibodiesDate forCompany Solid Tumor Therapy ApprovedActive Integedients By FDA. Target Indication TLS Herceptin 9/25/1998 No 2/12/2004 GenetechImclone Trastuzumab** EGF BreastMCC Ca No Erbitux 2/26/2004 Cetuximab VEGFR Colon Ca No Avastin** 9/27/2006 GenetechAmgen Bevacizumab VEGF Colorectal Ca No Vectibix Panitumumab CTLA-4EGFR Melanoma No Yervoy** 3/25/2011 BMS Ipilimumab Citation: DOI: Cai HH (2017) Tumor Lysis Syndrome Caused by Therapeutic Monoclonal Antibodies Approved by FDA. MOJ Immunol 5(5): 00169. 10.15406/moji.2017.05.00169 Copyright: Tumor Lysis Syndrome Caused by Therapeutic Monoclonal Antibodies Approved by FDA ©2017 Cai 3/3 6/8/2012 HER2 No Perjeta** Genetech Pertuzumab HER2 Breast Ca No Kadcyla** 2/22/20134/21/2014 GenetechEli Eilly Ado-Trastuzumab Emtansine Breast Ca No Cyramza** 9/4/2014 MSD Ramucirumab VEGFR2PD-1 MelanomaGastric Ca No Keytruda** 12/22/2014 Pembrolizumab PD-1 Melanoma No Opdivo** UnitedBMS Terap Nivolumab No Unituxin** 11/24/20153/10/2015 Eli Eilly Dinutuximab GD2 NeuroblastomaLung cancer No Portrazza** Necitumumab EGFR References 16. http://www.accessdata.fda.gov/drugsatfda_docs/ 1. 17. label/2013/125427lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ Cai HH (2016) Therapeutic Monoclonal Antibodies Approved by 2. FDACai HH in 2015.(2014) MOJ Molecular Immunology Pharmacovigilance: 3(2): 87. Safety Signal for Drug 18. label/2013/125486s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ Modification.Cai HH (2014) MOJ Risk Immunology Evaluation and 1(5): Mitigation 25. Strategy for Approved 19. label/2014/125477lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ 3. 4. Therapeutic Antibodies. MOJ Immunology 1(5): 28. 20. label/2014/125514lbl.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/ 5. rituide021902LBp1.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/ 21. tosicor062703LB.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ http://www.accessdata.fda.gov/drugsatfda_docs/label/1998/ 6. trasgen092598lb.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ 22. label/2014/125554lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ 7. label/2000/21174lbl.pdf label/2015/125516s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ http://www.accessdata.fda.gov/drugsatfda_docs/label/ 8. biologics/103948-5036_campath_lbl.pdf 23. 24. label/2015/761036Orig1s000lbledt.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/ 9. ibriide021902LB.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ 25. label/2015/125547s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ 10. label/2004/125084lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ 26. label/2015/761035s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ 11. label/2004/125085lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ 27. label/2016/761034Orig1s000lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/ 12. label/2006/125147s0000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ 28. label/2016/761041s000lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/ label/2009/125326lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ 29. label/2016/761038lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/ 13. 14. label/2011/125377s0000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ label/2017/761049s000lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/ 15. label/2011/125388s000,125399s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/ 30. label/2017/761069s000lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/ label/2012/125409lbl.pdf 31. label/2017/761078s000lbl.pdf Citation: DOI: Cai HH (2017) Tumor Lysis Syndrome Caused by Therapeutic Monoclonal Antibodies Approved by FDA. MOJ Immunol 5(5): 00169. 10.15406/moji.2017.05.00169.
Load more

Recommended publications
  • (Human Papillomavirus 9-Valent Vaccine, Recombinant), for Use In
    tools Approved Drugs FDA has approved a supplemental new drug propelled, joystick-controlled, easy-to-use application (sNDA) for Xtandi® colonoscope system. • The Food and Drug Administration (FDA) (enzalutamide) capsules in advanced has approved a supplemental biologics prostate cancer. • Varian Medical Systems (varian.com) has license application (sBLA) for the use of received 510(k) clearance from the FDA to Arzerra® (ofatumumab) (Genmab A/S, market the Nexus DR, a high resolution genmab.com) in combination with Drugs in the News imaging system for X-ray imaging using a fludarabine and cyclophosphamide for the digital X-ray detector. treatment of patients with relapsed chronic • Genentech (gene.com) has received a lymphocytic leukemia (CLL). second breakthrough therapy designation Approved Genetic Tests & from the FDA for Alecensa® (alectinib) Assays • Amgen (amgen.com) announced that the for the treatment of adult patients with FDA has approved the sBLA for Blincyto® advanced ALK-positive NSCLC who have • AstraZeneca (astrazeneca-us.com) (blinatumomab) to include new data not received prior treatment with an ALK announced that the FDA has approved a supporting the treatment of pediatric patients inhibitor. blood-based companion diagnostic for with Philadelphia chromosome-negative (Ph-) Tagrisso® (osimertinib). relapsed or refractory B-cell precursor acute • AbbVie (abbvie.com) submitted an sNDA lymphoblastic leukemia (ALL). to the FDA for Imbruvica® (ibrutinib) to treat patients with marginal zone lymphoma, • Merck Sharp & Dohme Corp.’s (merck.com) a form of non-Hodgkin’s lymphoma. FDA Approves Two-Dose Keytruda® (pembrolizumab) has received Vaccination Regime FDA approval in first-line non-small cell lung • Fate Therapeutics, Inc.
    [Show full text]
  • Alemtuzumab Comparison with Rituximab and Leukemia Whole
    Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in This information is current as Comparison with Rituximab and of September 27, 2021. Alemtuzumab Luca Bologna, Elisa Gotti, Massimiliano Manganini, Alessandro Rambaldi, Tamara Intermesoli, Martino Introna and Josée Golay Downloaded from J Immunol 2011; 186:3762-3769; Prepublished online 4 February 2011; doi: 10.4049/jimmunol.1000303 http://www.jimmunol.org/content/186/6/3762 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2011/02/04/jimmunol.100030 Material 3.DC1 References This article cites 44 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/186/6/3762.full#ref-list-1 by guest on September 27, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American
    [Show full text]
  • Study Protocol
    Official Title: A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST- LINE METASTATIC COLORECTAL CANCER (MODUL) NCT Number: NCT02291289 Document Date: Protocol Version 9: 18-Feb-2020 PROTOCOL TITLE: A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST-LINE METASTATIC COLORECTAL CANCER (MODUL) PROTOCOL NUMBER: MO29112 VERSION NUMBER: 9 EUDRACT NUMBER: 2014-001017-61 IND NUMBER: N/A TEST PRODUCT: Atezolizumab (MPDL3280A, RO5541267) Bevacizumab (RO4876646) Cobimetinib (RO5514041) Pertuzumab (RO4368451) Trastuzumab (RO0452317) Vemurafenib (RO5185426) Cetuximab And combinations thereof MEDICAL MONITOR: Dr. SPONSOR: F. Hoffmann-La Roche Ltd. DATE FINAL: See electronic date stamp below FINAL PROTOCOL APPROVAL Date and Time (UTC) Title Approver's Name 18-Feb-2020 15:44:34 Company Signatory CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered. Bevacizumab — F. Hoffmann-La Roche Ltd. Protocol MO29112, Version 9 DATES AMENDED: Version 1: 5 August 2014 Version 2: 29 October 2014 Version 3: 2 February 2015 Version 4: 30 November 2015 Version 5: 11 April 2016 Version 6: 24 November 2016 Version 7: 8 August 2018 Version 8: 19 December 2018 Bevacizumab — F.
    [Show full text]
  • = 'NH., Diseases, Central Nerrous System M)Ury and Different Foims of Mflannnation
    (12) INTERNATIONAL APPLICATION Pl;BLISHED 1. NDER THE PATENT COOPERATION TREATY (PCT) (19) World intellectual Property Organraation llIlllIlllIlIllllllllIlllllIIllIllIlllIlllllllllllIlllIllIlIlllIllIlIllIllIlIIIIIIIIIIIIIIIIIII International Bureau (10) International Publication Number (43) International Publication Date WO 2020/114892 Al 11 June 2020 (11.06.2020) W 4 P Gl I P 0 T (51) International Patent Classification: C07D 401/06 (200G 0 I) AGJK31/454 (200G 0l) C07D dt)J//4 (2006 01) A61P35/ttd (200G 0l) (21) International Application Number: PCT/EP2019/l)8 3014 (22) International Filing Date: 29 Nosember 2019 (29.11.2019) (25) Filing Language: Enghsh (26) Publication Language Enghsh (30) Priority Data: 1820972/i 1 03 December 20)8 (03 12 2018) EP (71) Applicant: MERCK PATENT GMBH IDE/DE]. Frm&(s- furter Strasse 230. 64293 DARMSTADT (DE) (72) Inventors: BUCHSTALLER, Hans-Peter. Ncc)sa&strasse G. G4347 GRIESHELVI (DE). ROHDICH, Feliru Saalbaus- tmssc 23. 64283 DARMSTADT (DE). (81) Designated States /unless i&themmse n&d&ct&md, /or e&ery hind of national protect«&n menial&le/ AF, AG, AL, AVI AO, AT. AU. AZ, BA, BB, BG, BH. B N. BR, BW, BY. BZ. CA. CH, CL, CN. CO, CR. C U, CZ. DE, DJ, DK. DM DO. DZ, EC. EE, EG. ES. FI, GB. GD. GE. GH, GM. GT. HN. HR. HU, ID, IL. IN, IR, IS. JO, JP, KE. KG, KH. KN, KP. KR. KW, KZ, LA. L C, LK. LR, LS, LU. LY. MA. MD, ME. WIG. MK. MN, MW, MX. MY. MZ. NA. NG. NI, NO. NZ. OM, PA. PE, PG. PH, PL. PT. QA, RO, RS.
    [Show full text]
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • Dinutuximab for the Treatment of Pediatric Patients with High-Risk Neuroblastoma
    Expert Review of Clinical Pharmacology ISSN: 1751-2433 (Print) 1751-2441 (Online) Journal homepage: http://www.tandfonline.com/loi/ierj20 Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma Jaume Mora To cite this article: Jaume Mora (2016): Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma, Expert Review of Clinical Pharmacology, DOI: 10.1586/17512433.2016.1160775 To link to this article: http://dx.doi.org/10.1586/17512433.2016.1160775 Accepted author version posted online: 02 Mar 2016. Published online: 21 Mar 2016. Submit your article to this journal Article views: 21 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierj20 Download by: [Hospital Sant Joan de Deu], [Jaume Mora] Date: 30 March 2016, At: 23:12 EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016 http://dx.doi.org/10.1586/17512433.2016.1160775 DRUG PROFILE Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma Jaume Mora Department of Pediatric Onco-Hematology and Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, Passeig Sant Joan de Déu, Barcelona, Spain ABSTRACT ARTICLE HISTORY Neuroblastoma (NB) is the most common extra cranial solid tumor of childhood, with 60% of patients Received 14 December 2015 presenting with high risk (HR) NB by means of clinical, pathological and biological features. The 5-year Accepted 29 February 2016 survival rate for HR-NB remains below 40%, with the majority of patients suffering relapse from Published online chemorefractory tumor. Immunotherapy is the main strategy against minimal residual disease and 21 March 2016 clinical experience has mostly focused on monoclonal antibodies (MoAb) against the glycolipid dis- KEYWORDS ialoganglioside GD2.
    [Show full text]
  • Combinations of Immunotherapy and Radiation Therapy in Head and Neck Squamous Cell Carcinoma: a Narrative Review
    2585 Review Article on Synergy in Action: Novel Approaches to Combining Radiation Therapy and Immunotherapy Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review Thomas J. Hayman1, Aarti K. Bhatia2, Krishan R. Jethwa1, Melissa R. Young1, Henry S. Park1^ 1Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA; 2Section of Medical Oncology, Department of Medicine, Yale School of Medicine, New Haven, CT, USA Contributions: (I) Conception and design: TJ Hayman, HS Park; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: TJ Hayman, HS Park; (V) Data analysis and interpretation: TJ Hayman, HS Park; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Henry S. Park, MD, MPH. Assistant Professor of Therapeutic Radiology, Yale School of Medicine, 35 Park Street, Lower Level, New Haven, CT 06520, USA. Email: [email protected]. Abstract: Radiation therapy and systemic therapy are the primary non-surgical treatment modalities for head and neck squamous cell carcinoma (HNSCC). Despite advances in our biologic understanding of this disease and the development of novel therapeutics, treatment resistance remains a significant problem. It has become increasingly evident that the innate and adaptive immune systems play a significant role in the modulation of anti-tumor responses to traditional cancer-directed therapies. By inducing DNA damage and cell death, radiation therapy appears to activate both innate and adaptive immune responses. Immunotherapies targeting programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) also have yielded promising results, particularly in the recurrent/metastatic setting.
    [Show full text]
  • TECENTRIQ® (Atezolizumab) Injection, for Intravenous Use DOSAGE FORMS and STRENGTHS Initial U.S
    of 4-6 cycles. Following completion of chemotherapy, TECENTRIQ 1200 HIGHLIGHTS OF PRESCRIBING INFORMATION mg IV, following by bevacizumab, every 3 weeks. These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for If the first infusion is tolerated, all subsequent infusions may be delivered over TECENTRIQ. 30 minutes. (2.2, 2.3) TECENTRIQ® (atezolizumab) injection, for intravenous use DOSAGE FORMS AND STRENGTHS Initial U.S. Approval: 2016 Injection: 1200 mg/20 mL (60 mg/mL) solution in a single-dose vial (3) RECENT MAJOR CHANGES CONTRAINDICATIONS Indications and Usage, Urothelial Carcinoma (1.1) 7/2018 None. (4) Indications and Usage, Non-Small Cell Lung Cancer (1.2) 12/2018 Dosage and Administration (2.3) 7/2018 WARNINGS AND PRECAUTIONS Warnings and Precautions, Pneumonitis (5.1) 12/2018 Immune-Mediated Pneumonitis: Withhold or permanently discontinue Warnings and Precautions, Hepatitis (5.2) 12/2018 based on severity of pneumonitis. (2.4, 5.1) Warnings and Precautions, Colitis (5.3) 12/2018 Immune-Mediated Hepatitis: Monitor for changes in liver function. Warnings and Precautions, Endocrinopathies (5.4) 12/2018 Withhold or permanently discontinue based on severity of transaminase or Warnings and Precautions, Infections (5.6) 12/2018 total bilirubin elevation. (2.4, 5.2) Warnings and Precautions, Infusion-Related Reactions (5.7) 12/2018 Immune-Mediated Colitis: Withhold or permanently discontinue based on severity of colitis. (2.4, 5.3) INDICATIONS AND USAGE Immune-Mediated Endocrinopathies (2.4, 5.4): TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody o Hypophysitis: Withhold based on severity of hypophysitis.
    [Show full text]
  • Alemtuzumab Comparison with Rituximab and Leukemia Whole
    Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in This information is current as Comparison with Rituximab and of September 29, 2021. Alemtuzumab Luca Bologna, Elisa Gotti, Massimiliano Manganini, Alessandro Rambaldi, Tamara Intermesoli, Martino Introna and Josée Golay Downloaded from J Immunol 2011; 186:3762-3769; Prepublished online 4 February 2011; doi: 10.4049/jimmunol.1000303 http://www.jimmunol.org/content/186/6/3762 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2011/02/04/jimmunol.100030 Material 3.DC1 References This article cites 44 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/186/6/3762.full#ref-list-1 by guest on September 29, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American
    [Show full text]
  • Horizon Scanning Status Report June 2019
    Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI Institute under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG- 2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the horizon scanning system has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions. A representative from PCORI served as a contracting officer’s technical representative and provided input during the implementation of the horizon scanning system. PCORI does not directly participate in horizon scanning or assessing leads or topics and did not provide opinions regarding potential impact of interventions. Financial Disclosure Statement None of the individuals compiling this information have any affiliations or financial involvement that conflicts with the material presented in this report. Public Domain Notice This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated. All statements, findings, and conclusions in this publication are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI) or its Board of Governors.
    [Show full text]
  • Management of Multiple Myeloma: the Changing Paradigm
    Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Jeffrey A. Zonder, MD Karmanos Cancer Institute Objectives • Discuss use of standard myeloma therapies when used as therapy after relapse • Consider patient and disease factors which might impact therapy decisions. • Describe off-label options for patients who are not protocol candidates. Line ≠ Line ≠ Line ≠ … POLICE LINE – DO NOT CROSS POLICE LINE – DO NOT CROSS POLICE LINE – DO NOT CROSS POLICE LINE – DO NOT CROSS POLI LINE – DO NOT Define “Line” • A pre-defined course of therapy utilizing agents either simultaneously or sequentially – Len/Dex – Len/Dex ASCT – Vel/Dex ASCT Len/Dex – VDT-PACE ASCT TD ASCT VPT-PACE LD • Pts who have had the same # of “lines” of Rx may have had vastly different amounts of Rx What Is Relapsed/Refractory Disease? • Relapsed: recurrence after a response to therapy • Refractory: progression despite ongoing therapy What Do We Know About the Pt’s Myeloma? • What prior therapy has been used? • How well did it work? • Did the myeloma progress on active therapy? • High-risk cytogenetics/FISH/GEP? What Do We Know About the Patient? • Age • Other medical problems – Diabetes – Blood Clots • Lasting side effects from past therapies – Peripheral Neuropathy • Personal preferences and values Choosing Therapy for Relapsed/Refractory Myeloma Proteasome IMiDs Anthracyclines Alkylators Steroids HDACs Antibodies Inhibitors Thalidomide Bortezomib Doxil Melphalan Dex Panobinostat Elotuzumab Lenalidomide Carfilzomib Cytoxan Pred Vorinostat
    [Show full text]
  • Federal Register Notice 5-1-2020 Pdf Icon[PDF – 358
    Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices 25439 confidential by the respondent (5 U.S.C. schedules. Other than examination DEPARTMENT OF HEALTH AND 552(b)(4)). reports, it provides the only financial HUMAN SERVICES Current actions: The Board has data available for these corporations. temporarily revised the instructions to The Federal Reserve is solely Centers for Disease Control and the FR Y–9C report to accurately reflect responsible for authorizing, supervising, Prevention the revised definition of ‘‘savings and assigning ratings to Edges. The [CDC–2020–0046; NIOSH–233–C] deposits’’ in accordance with the Federal Reserve uses the data collected amendments to Regulation D in the on the FR 2886b to identify present and Hazardous Drugs: Draft NIOSH List of interim final rule published on April 28, potential problems and monitor and Hazardous Drugs in Healthcare 2020 (85 FR 23445). Specifically, the develop a better understanding of Settings, 2020; Procedures; and Risk Board has temporarily revised the activities within the industry. Management Information instructions on the FR Y–9C, Schedule HC–E, items 1(b), 1(c), 2(c) and glossary Legal authorization and AGENCY: Centers for Disease Control and content to remove the transfer or confidentiality: Sections 25 and 25A of Prevention, HHS. withdrawal limit. As a result of the the Federal Reserve Act authorize the ACTION: Notice and request for comment. revision, if a depository institution Federal Reserve to collect the FR 2886b chooses to suspend enforcement of the (12 U.S.C. 602, 625). The obligation to SUMMARY: The National Institute for six transfer limit on a ‘‘savings deposit,’’ report this information is mandatory.
    [Show full text]